Aneurysm-express: Human abdominal aortic aneurysm wall expression in relation to heterogeneity and vascular events-rationale and design

European Surgical Research

Volumn 45, Issue 1, 2010, Pages 34-40

  Hurks, R ^a   Hoefer, I E ^a   Vink, A ^b   De Vries, J P P M ^a   Heijmen, R H ^c   Schoneveld, A H ^a   Kerver, M ^a   Pasterkamp, G ^a   Moll, F L ^a  

^a Experimental Cardiology   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

abdominal; Aortic aneurysm; Aortic diseases; Biobank; Biomarker; Cardiovascular outcome; Heterogeneity

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; AORTA ANEURYSM; ARTERY WALL; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

EID: 77955622555     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318160     Document Type: Article

References (42)

1. Best VA, Price JF, Fowkes FG: Persistent in-crease in the incidence of abdominal aortic aneurysm in Scotland, 1981-2000. Br J Surg 2003; 90:1510-1515.
2. Gillum RF: Epidemiology of aortic aneu-rysm in the United States. J Clin Epidemiol 1995; 48:1289-1298.
3. McPhee JT, Hill JS, Eslami MH: The impact of gender on presentation, therapy, and mor-tality of abdominal aortic aneurysm in the United States, 2001-2004. J Vasc Surg 2007; 45:891-899.
4. Lindholt JS, Norman P: Screening for ab-dominal aortic aneurysm reduces overall mortality in men: a meta-analysis of the mid-and long-term effects of screening for ab-dominal aortic aneurysms. Eur J Vasc Endo-vasc Surg 2008; 36: 167-171.
5. Pleumeekers HJ, Hoes AW, Hofman A, van Urk H, van der Does E, Grobbee DE: Select-ing subjects for ultrasonographic screening for aneurysms of the abdominal aorta: four different strategies. Int J Epidemiol 1999; 28: 682-686.
6. Lovegrove RE, Javid M, Magee TR, Galland RB: A meta-analysis of 21178 patients under-going open or endovascular repair of ab-dominal aortic aneurysm. Br J Surg 2008; 95: 677-684.
7. Schwarze ML, Shen Y, Hemmerich J, Dale W: Age-related trends in utilization and out-come of open and endovascular repair for abdominal aortic aneurysm in the United States, 2001-2006. J Vasc Surg 2009; 50:722-729.
8. Patterson BO, Holt PJ, Hinchliffe R, Loftus IM, Thompson MM: Predicting risk in elec-tive abdominal aortic aneurysm repair: a systematic review of current evidence. Eur J Vasc Endovasc Surg 2008; 36:637-645.
9. Golledge J, Tsao PS, Dalman RL, Norman PE: Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008; 118:2382-2392.
10. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al: ACC/ AHA 2005 Practice Guidelines for the man-agement of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Soci-ety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radi-ology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilita-tion; National Heart, Lung, and Blood Insti-tute; Society for Vascular Nursing; TransAt-lantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463-e654.
11. Rose GA, Blackburn H: Cardiovascular sur-vey methods. Monogr Ser World Health Or-gan 1968; 56: 1-188.
12. De Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT: Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 133-139.
13. Vignali DA: Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243:243-255.
14. Hellings WE, Pasterkamp G, Vollebregt A, Seldenrijk CA, De Vries JP, Velema E, et al: Intraobserver and interobserver variability and spatial differences in histologic exami-nation of carotid endarterectomy specimens. J Vasc Surg 2007; 46:1147-1154.
15. Boerma WG, van der Zee J, Fleming DM: Service profiles of general practitioners in Europe. European GP Task Profile Study. Br J Gen Pract 1997; 47:481-486.
16. Hellings WE, Moll FL, De Vries JP, Acker-staff RG, Seldenrijk KA, Met R et al: Athero-sclerotic plaque composition and occurrence of restenosis after carotid endarterectomy JAMA 2008; 299:547-554.
17. Hellings WE, Moll FL, de Vries JP, de Bruin P, de Kleijn DP, Pasterkamp G: Histologi-cal characterization of restenotic carotid plaques in relation to recurrence interval and clinical presentation: a cohort study. Stroke 2008; 39:1029-1032.
18. Hurks R, Peeters W, Derksen WJ, Hellings WE, Hoefer IE, Moll FL, et al: Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic dis-ease. Thromb Haemost 2009; 101:48-54.
19. Peeters W, Hellings WE, de Kleijn DP, de Vries JP, Moll FL, Vink A, et al: Carotid ath-erosclerotic plaques stabilize after stroke insights into the natural process of athero-sclerotic plaque stabilization. Arterioscler Thromb Vasc Biol 2009; 29:128-133.
20. Biomarkers and surrogate endpoints: pre-ferred definitions and conceptual frame-work. Clin Pharmacol Ther 2001; 69:89-95.
21. Haverkate F, Thompson SG, Pyke SD, Gal-limore JR, Pepys MB, European Concerted Action on Thrombosis and Disabilities An-gina Pectoris Study Group: Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
22. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela W J, Tsai J, et al: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
23. Eugster T, Huber A, Obeid T, Schwegler I, Gurke L, Stierli P: Aminoterminal propep-tide of type III procollagen and matrix metal-loproteinases-2 and-9 failed to serve as se-rum markers for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2005; 29: 378-382.
24. Sangiorgi G, DAverio R, Mauriello A, Bon-dio M, Pontillo M, Castelvecchio S, et al: Plasma levels of metalloproteinases-3 and-9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001; 104:I288-I295.
25. Golledge J, Clancy P, Jamrozik K, Norman PE: Obesity, adipokines, and abdominal aor-tic aneurysm: Health in Men study. Circulation 2007; 116:2275-2279.
26. Powell JT, Muller BR, Greenhalgh RM: Acute phase proteins in patients with ab-dominal aortic aneurysms. J Cardiovasc Surg (Torino) 1987; 28: 528-530.
27. Dawson J, Cockerill GW, Choke E, Belli AM, Loftus I, Thompson MM: Aortic aneurysms secrete interleukin-6 into the circulation. J Vasc Surg 2007; 45: 350-356.
28. Rohde LE, Arroyo LH, Rifai N, Creager MA, Libby P, Ridker PM, et al: Plasma concentra-tions of interleukin-6 and abdominal aortic diameter among subjects without aortic dil-atation. Arterioscler Thromb Vasc Biol 1999; 19: 1695-1699.
29. Shteinberg D, Halak M, Shapiro S, Kinarty A, Sobol E, Lahat N et al: Abdominal aortic aneurysm and aortic occlusive disease: a comparison of risk factors and inflammato-ry response. Eur J Vasc Endovasc Surg 2000; 20:462-465.
30. Fowkes FG, Anandan CL, Lee AJ, Smith FB, Tzoulaki I, Rumley A, et al: Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of in-flammation and hemostasis, not smoking or cardiovascular disease. J Vasc Surg 2006; 43: 474-480.
31. Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H, et al: Elevated circulat-ing levels of inflammatory cytokines in pa-tients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997; 17: 2843-2847.
32. Treska V, Topolcan O, Pecen L: Cytokines as plasma markers of abdominal aortic aneu-rysm. Clin Chem Lab Med 2000; 38:1161-1164.
33. Lombardo A, Biasucci LM, Lanza GA, Coli S, Silvestri P, Cianflone D, et al: Inflamma-tion as a possible link between coronary and carotid plaque instability. Circulation 2004; 109:3158-3163.
34. Mauriello A, Sangiorgi G, Fratoni S, Palm-ieri G, Bonanno E, Anemona L, et al: Diffuse and active inflammation occurs in both vul-nerable and stable plaques of the entire coro-nary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005; 45:1585-1593.
35. De Kleijn DP, Moll FL, Hellings WE, Ozsar-lak-Sozer G, de Bruin P, Doevendans PA, et al: Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardio-vascular events. Arterioscler Thromb Vasc Biol 2010; 30: 612-619.
36. Shimizu K, Mitchell RN, Libby P: Inflam-mation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006; 26: 987-994.
37. Iribarren C, Darbinian JA, Go AS, Fireman BH, Lee CD, Grey DP: Traditional and novel risk factors for clinically diagnosed abdomi-nal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. Ann Epidemiol 2007; 17: 669-678.
38. Vainas T, Lubbers T, Stassen FR, Herngreen SB, van Dieijen-Visser MP, Bruggeman CA, et al: Serum C-reactive protein level is associ-ated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 2003; 107:1103-1105.
39. Lederle FA, Johnson GR, Wilson SE, Ballard DJ, Jordan WD Jr, Blebea J, et al: Rupture rate of large abdominal aortic aneurysms in pa-tients refusing or unfit for elective repair. JAMA 2002; 287:2968-2972.
40. Nicholls SC, Gardner JB, Meissner MH, Jo-hansen HK: Rupture in small abdominal aortic aneurysms. J Vasc Surg 1998; 28:884-888.
41. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH: Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997; 96:2228-2232.
42. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al: Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental ab-dominal aortic aneurysms. J Clin Invest 2000; 105:1641-1649